FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Tiludronate infusion in the treatment of bone spavin: a doub...
Equine veterinary journal2010; 42(5); 381-387; doi: 10.1111/j.2042-3306.2010.00120.x

Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial.

Abstract: Tiludronate regulates bone remodelling through a decrease of the resorptive process and should therefore ameliorate the remodelling processes active in osteoarthritis of the distal tarsal joints ('bone spavin') and alleviate pain associated with abnormal bone lysis. Objective: To confirm the efficacy of tiludronate, administered as a single infusion at a dose of 1 mg/kg bwt, in the treatment of bone spavin in the horse. Methods: A double blind placebo controlled trial on 108 clinical cases of bone spavin was undertaken. The lameness score of the lamest limb was assessed following distal tarsal analgesia of the contralateral limb and followed-up using the same procedure throughout the study. Bone spavin in the lamest limb was confirmed by distal tarsal analgesia and radiography. Horses were treated at Day 0 and reassessed 60 days later after controlled exercise. A second nonblinded treatment was given to unresponsive horses and all horses were re-examined at Day 120. Exercise levels were recorded at each examination. Results: Eighty-seven horses completed the trial as per the protocol. The tiludronate horses were significantly less lame than the placebo horses (P = 0.0318). Horses treated at Day 60 with tiludronate showed further improvement in lameness at Day 120 (P = 0.0096 and P = 0.0034 for horses treated with tiludronate and placebo at Day 0, respectively). The only significant difference in radiographic findings between tiludronate and placebo was for presence of periarticular osteophytes (P = 0.006). Conclusions: Tiludronate treatment is proven to be effective in bone spavin in horses in association with a controlled exercise programme. Conclusions: Tiludronate in combination with controlled exercise offers an alternate medical treatment for bone spavin.
Get Full Text
Publication Date: 2010-07-20 PubMed ID: 20636772DOI: 10.1111/j.2042-3306.2010.00120.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article discusses a trial on the effectiveness of tiludronate, administered as a single infusion, in treating bone spavin in horses. The study concluded that tiludronate, in conjunction with a controlled exercise program, was effective and could provide alternative treatment for bone spavin.

Introduction to Research

  • The research focused on testing the efficacy of the drug tiludronate in treating bone spavin — a form of osteoarthritis that affects horses.
  • Tiludronate is a drug known to regulate bone remodeling by reducing the resorptive process, which involves the breakdown of bone tissue.
  • The researchers believed that tiludronate could slow down the active remodeling processes associated with osteoarthritis and consequently relieve the pain caused by abnormal bone lysis, the breakdown of bone tissue.

Research Methodology

  • The researchers conducted a double-blind placebo-controlled trial involving 108 clinical cases of bone spavin in horses.
  • The lameness score of the lamest limb in each horse was measured following distal tarsal analgesia of the contralateral limb, and the same procedure was repeated during the study for consistency.
  • Each horse was treated on Day 0 and reassessed 60 days later after undergoing a regimen of controlled exercise. Unresponsive horses received a second treatment, and all horses were re-examined at Day 120.

Results of the Study

  • 87 of the horses completed the trial according to the protocol.
  • Horses treated with tiludronate were significantly less lame than those who received the placebo, proving that tiludronate is efficient in treating bone spavin in horses.
  • There was further improvement in the lameness of the horses treated with tiludronate at Day 60 by Day 120.
  • The only significant radiographic differences between the horses treated with tiludronate and those with placebo were the presence of periarticular osteophytes – a sign of more advanced bone disease.

Conclusions

  • The trial concluded that tiludronate treatment, in conjunction with a controlled exercise programme, is effective in treating bone spavin in horses.
  • The findings suggest that a combination of tiludronate and controlled exercise could serve as an alternative medical treatment for bone spavin.

Cite This Article

APA
Gough MR, Thibaud D, Smith RK. (2010). Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial. Equine Vet J, 42(5), 381-387. https://doi.org/10.1111/j.2042-3306.2010.00120.x

Publication

Equine veterinary journal
ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 42
Issue: 5
Pages: 381-387

Researcher Affiliations

Gough, M R
  • CEVA Animal Health, 90 The Broadway, Chesham, Bucks, UK.
Thibaud, D
    Smith, R K W

      MeSH Terms

      • Animals
      • Bone Density / drug effects
      • Bone Density Conservation Agents / therapeutic use
      • Diphosphonates / therapeutic use
      • Double-Blind Method
      • Female
      • Hindlimb / pathology
      • Horse Diseases / drug therapy
      • Horses
      • Lameness, Animal
      • Male
      • Osteoarthritis / drug therapy
      • Osteoarthritis / veterinary

      Citations

      This article has been cited 12 times.
      1. Vergara-Hernandez FB, Nielsen BD, Colbath AC. Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective. Animals (Basel) 2022 Jul 3;12(13).
        doi: 10.3390/ani12131722pubmed: 35804621google scholar: lookup
      2. Magri C, Schramme M, Febre M, Cauvin E, Labadie F, Saulnier N, François I, Lechartier A, Aebischer D, Moncelet AS, Maddens S. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study. PLoS One 2019;14(8):e0221317.
        doi: 10.1371/journal.pone.0221317pubmed: 31465445google scholar: lookup
      3. Mitchell A, Watts AE, Ebetino FH, Suva LJ. Bisphosphonate use in the horse: what is good and what is not?. BMC Vet Res 2019 Jun 24;15(1):211.
        doi: 10.1186/s12917-019-1966-xpubmed: 31234844google scholar: lookup
      4. Lacitignola L, Luca P, Santovito R, Comite MSD, Crovace A. Nutritional secondary hyperparathyroidism in two ponies. Open Vet J 2018;8(2):149-153.
        doi: 10.4314/ovj.v8i2.6pubmed: 29765869google scholar: lookup
      5. Richbourg HA, Mitchell CF, Gillett AN, McNulty MA. Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial. BMC Vet Res 2018 Mar 20;14(1):105.
        doi: 10.1186/s12917-018-1423-2pubmed: 29554967google scholar: lookup
      6. Hunter BG, Duesterdieck-Zellmer KF, Larson MK. Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses. PeerJ 2015;3:e889.
        doi: 10.7717/peerj.889pubmed: 25945303google scholar: lookup
      7. Duesterdieck-Zellmer KF, Moneta L, Ott JF, Larson MK, Gorman EM, Hunter B, Löhr CV, Payton ME, Morré JT, Maier CS. Effects of low and high dose intraarticular tiludronate on synovial fluid and clinical variables in healthy horses-a preliminary investigation. PeerJ 2014;2:e534.
        doi: 10.7717/peerj.534pubmed: 25237596google scholar: lookup
      8. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res 2012 Nov;1(11):297-309.
        doi: 10.1302/2046-3758.111.2000132pubmed: 23610661google scholar: lookup
      9. Moreau M, Rialland P, Pelletier JP, Martel-Pelletier J, Lajeunesse D, Boileau C, Caron J, Frank D, Lussier B, del Castillo JR, Beauchamp G, Gauvin D, Bertaim T, Thibaud D, Troncy E. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011 Jun 21;13(3):R98.
        doi: 10.1186/ar3373pubmed: 21693018google scholar: lookup
      10. Tippen SP, Metzger CE, Sacks SA, Allen MR, Mitchell CF, McNulty MA. Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses. Equine Vet J 2025 Mar;57(2):513-521.
        doi: 10.1111/evj.14119pubmed: 38924597google scholar: lookup
      11. Reis IL, Lopes B, Sousa P, Sousa AC, Caseiro AR, Mendonça CM, Santos JM, Atayde LM, Alvites RD, Maurício AC. Equine Musculoskeletal Pathologies: Clinical Approaches and Therapeutical Perspectives-A Review. Vet Sci 2024 Apr 26;11(5).
        doi: 10.3390/vetsci11050190pubmed: 38787162google scholar: lookup
      12. Wilcox CV, Knych HK, Katzman SA, Arthur RM, Rodriguez V, Finno CJ. Effect of clodronate on gene expression in the peripheral blood of horses. J Vet Pharmacol Ther 2024 May;47(3):187-192.
        doi: 10.1111/jvp.13424pubmed: 38197553google scholar: lookup
      Subscribe to our newsletter
      Join 99,002 horse owners like you who receive our email updates on horse health and nutrition.